Abstract
The ovarian cancer is one of the frequent cancers among women being diagnosed after cervical and breast cancer. The CA ovary is dreaded because even after successful treatment of the primary malignancy, the disease comes back and becomes resistant to conventional management. The prognosis in ovarian cancer management is mostly unsatisfactory, maybe because of the presence of ovarian cancer stem cells (OCSC). The hypothesis is that OCSC causes the recurrence of the ovarian malignancy. The OCSC can be identified by the presence of different markers and marker combinations. The assumptions are that CD44+, CD24+, CD117+, CD133+ and ALDH1+ could be the markers of ovarian cancer stem cells. The epithelial ovarian malignancy if proved as a stem cell disease, then it changes the entire management scenarios. Maybe, this will be the first step in managing the ovarian malignancy in the future.